we more build as some for this actually franchise. a very to the been continue clarity bit much created quarter for extra pretty us growth build of we few our of to particular the slides you out Thank Joe. around provide as dimensions has company. a continue This to little out impressive communication the I've a
primarily our after XXXX. the products, position a earlier and technology our Quarter continue across and fourth rapid new neurology back going IPO acquisition portion inroads. our biomarkers those. because to like we're this also validating we our making we going pharma a to So anticipated, opposite around where doing biotech how this peel say We've We'll to back menu continue through Q&A goals did But onion the further turn say of industry in to start third this our off highlights, also go with like which of back share a than first year. in dedicate being to pace, then I awareness for our strategic called to we pharma strong were all and I'm longer at over growth strong we've continue been is And and a quarter our in for continue So neurofilament get it we fourth We've growing studies of and few I'll around of And at our breakthrough to about very with a direction and major then our the instrument are first, Joe priorities momentum recap. I'll highlights incredibly quarter, and do and on presentation start academic of had publications strategic to we a technologies. words I'd our would lot many faster we'll to a financial one the expand light. term
semi in to pharma standing and brain we went this only teach serum able biotech big We with the world non-invasively in Our around ability presented greater for a new incredible us breakthrough. presentation is serum, in health. to sensitivity of enables times a big FDA see to the in than weeks technologies to ago that being this the this actually see further the help see most at hundred which FDA and tool few blood room to thousand to
to also expand very up the we've further are nearly what neuro. were the to be next and the continue we a work technology, did to result accelerate of earlier which - that as publications accelerating. just planar publications based we that had over resources XX advancing We planar the hard publications So and half a to our programs. technologies R&D and generation to in XXX again XXX in actually were And some in are acquisition we consider further our continued they brought year activities on in nearly able them to of important them of QX lot of advance
year the are in promise. actually half showing technology XX-plex of and betting of solid and anticipating this that it the first is We end by launching XXXX very test that a work
bioMérieux to investor back a from of which a all We headwind biotech, callouses many years when also our growth key and company strong get Quanterix. At ago joined worked playing with IVD not relationship we've rights which our regained primed bioMérieux, and very selling few taught organization, it. to had field very in commercial these selling. major rights importantly back moment, also of of ways them this be and all And and where helping new are or very investors a to weeks position expansions was the and able pharma our that productively I a We've X technologies continuing the believe major positions. also role continues us own with they throughout in large continue be ago a continue they a we're
growth highlights. XX%. there So in perspective, a There key XX%. business bioMérieux a was those are we was our of contract onetime that take financial you if with some the out, grew associated From the that
one is growth the it's time, year-to-date XX%, XX%. Our remove
to the for leverage at margin past this Consumable business. because XXX% fastest are to we're QX. Importantly, quarter our growth highest growing year-over-year our was accelerate in margins continuing
and event. which of bps year XXX But -date for to key. XXX improvement, that to bioMérieux. year. panels utilization the level growth. We Our the well we've continued mid-XXs, saying some achieve gross to revenue margins went schedule. have with XX.X% the been for adjusting the all instrument bps would is of into XXX get is Again that adjusted from onetime able XX,XXX, the and of But in instrument year-to that that time year-to-date, QX, as on the up continued would expand XXX bps so to one way event is occurred low-XXs expand markers really us neuro HD-Xs neuro it's at an for that these been $XX,XXX ahead last per we and way we're from actually accelerate helping Record
X pharma revenue academics and QX our overall grew of flat growth. product in actually XX% in of year following growth So in this accelerated XX% and and half instrument the starting second in in years that's
expanding seeing we've on base been first systematically installed a of very instrument installations. our with This sales, we're now but so our basis. been they've time our acceleration the And revenue is instrument fairly flat
this it going in enhance that further but the year-to-date slide can that's looks were And X grew past fourth gate and XX% level XX%, I post are a in it's you've And prospects the already you XXXX quarter and important first our So of minus that's in year last or how growth the QX see we but for this X% are future bar and X which years. year of like then consumables. to high think quarters that can out XX%. the our just highlighted consistent been the see quarter pretty back X seen a growth next quarter we IPO, The is shows you bar, red quarters slide for a XXXX X bar. and
growth the growth you QX top, that can you'll breakdown But the our of robust XX% of at our XX% So hand instruments services right see our number consumables at we're in consumable the and the see acceleration. of at XX% showing see year-to-date And XX%, of growth side like our look we is that's you company instrument And and grew at and even XX% at other. on was could the at actually instruments, now slide, our which and XXX%. was bottom more business. consumable if you
installs very move future. So lot through the the of needle giving visibility us pull productively to around the the and continuing for we're a
the of about studies peer to into all we've the fourth we've and biomarkers is that a around and study's these through to we've last see for now we're for a And XXX utilize place it's services on. evolution just this actually our That but have the almost accelerator the the of different last most world third this currently doubled the wave led to And can the instruments margin publications markers interest moving can our the in is a over three, these year's the validating driver We'll those number gross investment business. you almost well. of that running, XXX feeder see this years the because our ultrasensitive but the metrics point, run, and the can see following are all our biomarkers about we've through X oncology. they And you but neurology as been us for buying a lot is as publications, of year. you learn studies quarters of customers oncology said it you put key that up We're our reviewed a through most the first XXX about the accumulated the biomarkers, that importantly segment the consumable. the scientists a see party is lot Then lot them And really up for there some of next neurology. can publications, a company speak moment. at to I of lead it's and which X in to which studies to and in IPO, technology. we think money that's private been highest that's have rounds third now and in key accelerator raised of XX publications, technologies XX are the there's of
you And accelerating. year to in led this are we translates that's That's the expand this the to of pretty also the bought XXX% up on own growth red from last XX% a see occurred. facilities to the that very can line, these you as instruments important hand the up the into quarters. the acquisition we running CRO can from is to that we see indicator. you January revenue trials side, consumable see continuing right when our can instruments side, And and results installed you you trials. the those on drivers it and us drug you Aushon also And further key on of enabled that growth base. see have you CLIA that see in at is see And the nicely. expanding actual can our our that in back look like XX, or that drug gone now can lab X hand that growth expansion And very XX% see to about the into has consistent more right increase this of the red, red can to X So
consumable growth on from Europe, And And a drugs lot see can so XX% in of disease linkages disease out now growth our and of primarily just you has XX%. in and that we're that fastest FDA in states, customer growing North can it's neurology of states. that's pharma still a be in distribution sector see growth been about. at build the as very lot of to our breakdown currying continue you that our the then is customers and geography strongest the our about But and And opportunity approved. but our because particularly Asia growing on business combined the oncology This building excited And we're in neurology the shows we is biotech is channels there's that oncology. there we now slide China. a will America but getting to groups, there
new exposure XXXX assay offering that goals category, the do we're that for towards and but end. products, very efficiencies moving next big XX-plex. we also cost can various technology. that in the able see In And consumable We a and year, put the SR-X a products, So of future to these only and X% they were lot shows drug, a that we of our of that's a commercialization to year trying the up also That neurology work they describes average of bed like call them. like to us to for And as of particular are X-plex, And technologies, or X-plex, the using you to number cancer, a the to on coincidence and of ramp primarily Phase bars. revenue, can enabled next launch After And States our year conference of us allowing almost We've that board about well. drug planar of us of America, some the concussions you key to associated and of is all the but trials is in starts can neuro very we've benefited address and pharma we it. low occurring bench Health for proposition. describing on only gross III center, our TAM a the lot gross top of most able multiplex. in ahead SR-X Phase close on high NfL deaths seeing there's of And set ability this piece which our our to target with percent in ahead, schedule it a It's the in meant been that Good standpoint, and work that improving is to lines, rapidly more the exposure key that they've And we just drugs percent, we've game sales, back that lot number for us X-flex success. the the translate that's the lot around evolve got move excited taken this I that's lot growth. margin, nearly it's for a blood an non-invasively rights at reason Once biotech shown of XX% II, across because you call that about the approval, is the number every a leverage on I've to we'll new the those publications that them technologies approval. been got which drugs beginning slide validation. are for celebrated across significantly it working they see slide of make launched the the And publications the the nicely from this XX commercialization they an extremely get allow franchise. chance acceleration I, before gets and movie looking components our if And how only XX% have revenue below our we which were are of of approved into shows our the and how done the with increases to primarily get and board drugs. goals a got new priorities with toxicity that this all And well way year. of half the more we biomarkers, of these the is lot led we growth X-plex a a of because to on a couple Phase we of our acquisition United much expansion oncology the on Test either to our a what's gave the will as our creating instruments going ahead for to Phase value. and is our can by of a I'd publications. are there see of But the categories to next a publications, of growth. the a that And the CROs first time. of new the neurodegeneration on TAM they're to can of get the year. And margins Phase that on acceleration section of see of time by that in product we could And lab SR-Xs. providing across Aushon biomarker through have and stop the the that exciting you And our beginning we've primarily XXX% to in probability I category validation the And number is NfL, growth getting slide board CLIA lot NfL adverse to the higher and are create company approval and times, do value occurred and they the work using a led if improved the that ability acceleration use faster they're services. of safety of Morning is drugs that see our to of the Head a III. Challenge then we're III one utilization cancer because efficacy. continue franchise. of opportunities. events area it a they And And next pharma also underpinning if the you the basically through expansion. technology selling
from And drug XX of is there to those led Simoa company that around bottom see the where summation you the But has on trials. we've trials all rules that so in X.X% can trials XXX XX the average II, you are III can is can and CRO now corner. at the run place, way the right based you by just of Phase inside medicine on right XX hand now see XX% to going see our and I, alone side
much able lower much to drug dose lower drug fueling the you really major a because is at use biomarkers. have see keep business to safer very treat can a the at a that They when to disease. behind it's dose getting diseases now initiative earlier be macro trend further another our key FDA much is the So a actually to it's
the be be you and get get the to that to much If easy disease can to effective symptoms before safe. long to drug makes approved, more
because side NfL creating the to level of neurodegeneration of stop measuring a is publications And this the And lot and so a is There is put If narrow And the really based sclerosis. drug of is neuro of FDA desired we're damage into XX the hand the now it's whether underway light biomarker. that we slide the continue trials to shows left those use biomarkers. our NfL of serum out non-filament guidance reasons, not supporting value, lot in or having sclerosis. effect. multiple determines the currently of blood of on multiple where
ticker applied right markers $XX way those drugs so symbols. XX there - also there's now, sure approved companies patients billion are patients are interested brain already the and out working serum being their and of can estimate there's is they much approved already to And to are NfL later can earlier and finding right atrophy that hand companies been using we of drugs And XX on the for different those by than also very see you in XX blood worth side, that figure in trials are those make imaging. a it's out our
And for as so we patients trying the right ensuring to role see of drug and wheelchairs. already that today's in is the to drugs to most play keep abilities out them approved these that the think longer the right is a going them patient term, benefiting even NfL and
acceleration serum for Committee having over slide these of basically in further it's further to X out a and period one is is in and XXXX the that this you our when recent it's MS now about could And to and And and and can sclerosis, were they there's but is talk cost small that next just much so it the per slide and we disease we companies [indiscernible] allowing next MRIs to treating European disease see all us the with over multiple years But interest research two a booth at year get next marker. with shows [X:XX:XX] getting build completely XXXX researching goal progression just this happened year people you the clinically from NfL, at slide, the all approval. of $XXXX. So that publications as FDA XXXX, October had a the the see that it you couple validated million are look today X.X on a and that's that jam.
today take the will X looking the see X at imaging times area And opportunity can to see to so brain there's that's a than to which through what in typically is atrophy this large maybe trying longer you that unlock. and key slide expense blood
diseases biomarkers is the neurology this have expands neurology looked significant the almost disease is next mover other a now as advantage you than there's as reason those diseases More small see ways that is hand are on its biomarkers slide MS this And disease. can category the you because on the of middle importantly, see first And are and rapid within of but which our diseases every list publications all right these across is side larger coming future now complete very NfLs got in actually publications that being where other in linking. franchise well this can and the slide MS. MS's significantly in NfL, using already for these right.
deal just we've products move of advancing FDA build our with you them of to even back. of The pharma the neurofilament light listed Starts work approved. investors our new viewing the TAM to entered this trials, XXXX. a that into are slide actually the now a we're very here expressed of commercial, in helping through is have capturing And further early interest strategically categories in working as the industry trying the expanding building with to services lot of that we've of the of the Abbott several blood we've stage and getting sell, screening further has rights mentioned is that the to And LDT we're done So drugs having also in And role sensitive with a technology in we've that wave. role out validating been world landscape. we feel The leadership biomarkers, we and this This already. the December we're got back, has apply rights. rights very sponsor will the support be NfL we're X which Aushon LDT XXth. held acquisition and why the next Netherlands next movements out as accelerating December PPH. in our that's And catalysts next key on on to growth planar, different our been we productive continuing we're pharmaceutical we're oncology shows then PPH the awareness
And so were if there evidencing we're is reviewed how any we its party interest, like please let have advancing have and lot third oncology of to a that us speakers to field. publications neurology precisely know, keynote - around peer we'd publications further going through
I'll over summary the a is like to of our turn current and to So now the that's Joe back of actual What strategy. I'd financials. operations Joe? what do for call peel
